Skip to main content

Table 5 The pooled estimated rate of symptom relief and the incidence rate of complications in DAs- and surgery-treated patients

From: Are dopamine agonists still the first-choice treatment for prolactinoma in the era of endoscopy? A systematic review and meta-analysis

  DAs Surgery
Pooled result Number of studies Number of patients Pooled result Number of studies Number of patients
Vision impairment improvement rate 0.57 (0.38, 0.74) 14 176 0.68 (0.51, 0.82) 11 114
Headache improvement rate 0.86 (0.72, 0.94) 4 35 0.80 (0.32, 0.97) 3 95
Menstrual disturbance improvement rate 0.71 (0.16, 0.97) 6 123 0.68 (0.62, 0.74) 3 226
Galactorrhoea improvement rate 0.89 (0.72, 0.96) 6 29 0.33 (0.01, 0.94) 3 176
Incidence rate of ACTH insufficiency 0.10 (0.06, 0.16) 9 286 0.25 (0.13, 0.43) 11 387
Incidence rate of TSH deficiency 0.19 (0.12, 0.28) 7 194 0.24 (0.14, 0.38) 12 475
Incidence rate of hypopituitarism 0.29 (0.13, 0.54) 4 99 0.17 (0.06, 0.38) 11 709
Incidence rate of diabetes insipidus NA NA NA 0.17 (0.12, 0.25) 27 1616
  1. Das dopamine agonists, NA not applicable, because the data was not provided by included studies